Takeda
Clinical trials sponsored by Takeda, explained in plain language.
-
New pill hopes to calm Crohn's Flare-Ups
Disease control Not yet recruitingThis early-stage study tests a new drug called zasocitinib (TAK-279) in 20 adults with active Crohn's disease who have not responded to other treatments. The main goal is to see if the drug is safe and how it affects inflammation in the gut. Participants will take the drug for 12…
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jul 02, 2026 01:00 UTC
-
Takhzyro under the microscope: Real-World safety check for rare swelling disease
Disease control Not yet recruitingThis study looks at how safe and effective Takhzyro is for teenagers and adults with hereditary angioedema (HAE) in everyday medical care in South Korea. HAE is a rare condition that causes sudden swelling under the skin or inside the body. The study will track side effects and h…
Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to cut blood removal in rare cancer
Disease control Not yet recruitingThis trial tests rusfertide, an injected drug, in Japanese adults with polycythemia vera, a rare blood cancer that causes too many red blood cells. The goal is to see if rusfertide can keep red blood cell levels under control and reduce the need for phlebotomy (blood removal). Al…
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kidney transplant patients: drug targets rejection
Disease control Not yet recruitingThis study tests a drug called mezagitamab in people who have had a kidney transplant and are experiencing a type of rejection called antibody-mediated rejection (AMR). AMR happens when the body's immune system attacks the donor kidney, which can lead to kidney failure. The study…
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug aims to ease anemia in bone marrow cancer patients
Disease control Not yet recruitingThis Phase 3 trial tests whether elritercept can improve anemia in people with myelofibrosis who are already taking ruxolitinib. About 324 participants will receive either elritercept or a placebo for at least 9 months. The main goal is to see if the drug reduces the need for red…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug aims to cut transfusions for MDS patients
Disease control Not yet recruitingThis study tests a drug called TAK-226 (Elritercept) in 27 Japanese adults with lower-risk myelodysplastic syndromes (MDS) who need regular blood transfusions. The goal is to see if the drug can help them go without transfusions for at least 8 weeks. Participants will receive inj…
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Study examines which IBD drugs are safer for seniors
Knowledge-focused Not yet recruitingThis study looked at nearly 24,000 older adults (65+) with ulcerative colitis or Crohn's disease to see if certain advanced treatments lead to more infections. Researchers compared patients taking ENTYVIO, TNF-alpha inhibitors, or ustekinumab using Medicare claims data from 2016 …
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Egyptian HAE patients to be studied for better care insights
Knowledge-focused Not yet recruitingThis study will collect information from medical records and routine clinic visits of 100 people in Egypt with hereditary angioedema (HAE) type I or II. The goal is to understand how the condition is diagnosed and managed in current medical practice. No new treatments are being t…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study tracks Real-World impact of fruquintinib on advanced colon cancer
Knowledge-focused Not yet recruitingThis study will follow 110 adults in Poland with metastatic colorectal cancer (cancer that has spread) who are taking fruquintinib after at least two prior treatments. Researchers will track how long patients live without their cancer getting worse and their overall survival, usi…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New hope for rare blood disorder: study reviews real-world use of enzyme therapy
Knowledge-focused Not yet recruitingThis study looks back at medical records of people with congenital thrombotic thrombocytopenic purpura (cTTP), a rare inherited blood disorder that causes dangerous blood clots. Participants received a manufactured version of the missing ADAMTS13 enzyme through an early access pr…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Do patients understand their home infusion guides? new survey aims to find out
Knowledge-focused Not yet recruitingThis survey will ask about 60 people—patients with Gaucher disease, their caregivers, and home infusion nurses—how well they understand and use educational materials for at-home VPRIV infusions. The materials include an infusion diary, a guide, and an emergency plan. The goal is …
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC